SI
ATXS

Sofinnova Investments’s Astria Therapeutics ATXS Stock Holding History

Sofinnova Investments’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-85,640
Closed -$943K – 62
2024
Q3 		$943K Buy
85,640
+24,948
+41% +$277K 0.07% 56
2024
Q2 		$552K Buy
+60,692
New +$593K 0.03% 76

Other funds holding ATXS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Sofinnova Investments's ATXS Position: Q4 2024 in Review

Sofinnova Investments sold out of Astria Therapeutics (ATXS) in Q4 2024, closing a stake of 85,640 shares — an estimated $943K sold.

Sofinnova Investments first reported a position in ATXS in Q2 2024 and held it in 2 quarters. The position peaked at $943K in Q3 2024. 110 funds tracked by Wall St. Rank hold ATXS as of Q4 2024.

  • Sofinnova Investments reported no remaining Astria Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Sofinnova Investments sold 85,640 Astria Therapeutics shares in Q4 2024, an estimated $943K.
  • Sofinnova Investments first reported a position in Astria Therapeutics in Q2 2024 and held it in 2 quarters.
  • Sofinnova Investments's Astria Therapeutics position peaked at $943K in Q3 2024.
  • 110 funds tracked by Wall St. Rank held Astria Therapeutics as of Q4 2024.

Based on Sofinnova Investments's 13F filing for Q4 2024, filed 14 Feb 2025.